[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100138831":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":68,"centralContacts":10,"locations":10,"responsibleParty":73,"collaborators":75,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":10,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":10,"enrollmentInfo":88,"targetDuration":10,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":10,"overallStatus":97,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":10},{"fullName":5,"class":6},"Organon and Co","INDUSTRY",[8,18,22,25,29,33,37,41],{"label":9,"type":10,"description":11,"interventionNames":12},"Esophageal Cancer Cases",null,"Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.",[13,14,15,16,17],"Drug: Alendronate","Drug: Etidronate","Drug: Ibandronate","Drug: Risedronate","Drug: Raloxifene",{"label":19,"type":10,"description":20,"interventionNames":21},"Comparison Sample (Case-Cohort)","Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.",[13,14,15,16,17],{"label":23,"type":10,"description":24,"interventionNames":10},"Non-treated Comparators","Participants who did not initiate treatment of osteoporosis with a study drug",{"label":26,"type":10,"description":27,"interventionNames":28},"Alendronate","Participants initiating treatment for osteoporosis with alendronate",[13],{"label":30,"type":10,"description":31,"interventionNames":32},"Etidronate","Participants initiating treatment for osteoporosis with etidronate",[14],{"label":34,"type":10,"description":35,"interventionNames":36},"Ibandronate","Participants initiating treatment for osteoporosis with ibandronate",[15],{"label":38,"type":10,"description":39,"interventionNames":40},"Risedronate","Participants initiating treatment for osteoporosis with risedronate",[16],{"label":42,"type":10,"description":43,"interventionNames":44},"Raloxifene","Participants initiating treatment for osteoporosis with raloxifene",[17],[46,51,55,59,64],{"type":47,"name":26,"description":10,"armGroupLabels":48,"otherNames":49},"DRUG",[26,19,9],[50],"FOSAMAX®",{"type":47,"name":30,"description":10,"armGroupLabels":52,"otherNames":53},[19,9,30],[54],"DIDRONEL®",{"type":47,"name":34,"description":10,"armGroupLabels":56,"otherNames":57},[19,9,34],[58],"BONIVA®",{"type":47,"name":38,"description":10,"armGroupLabels":60,"otherNames":61},[19,9,38],[62,63],"ACTONEL®","ATELVIA®",{"type":47,"name":42,"description":10,"armGroupLabels":65,"otherNames":66},[19,9,42],[67],"EVISTA®",[69],{"name":70,"affiliation":71,"role":72},"Alec Walker, MD, DrPH","World Health Information Science Consultants, LLC","STUDY_DIRECTOR",{"type":74,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[76],{"name":71,"class":77},"OTHER","100138831","observational-study-of-incidence-rates-of-esophageal-cancer-in-women-taking-medications-for-the-prevention-or-treatment-of-osteoporosis-mk-0217a-352-100138831",true,"NCT01077817","Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women","Inclusion Criteria:\n\n* Cases:\n\n  * Women in the database aged 55 or older between 1996 and 2008 with diagnosis of esophageal cancer\n* Comparator Controls:\n\n  * Each case was matched to all women in the random subcohort of 25,000 who had the same year of birth as the case and were in the database at the time of diagnosis.\n\nExclusion Criteria:\n\n* Women with diagnosis of any other cancer or Paget's Disease or who have received oral or intravenous steroids before the index date",false,"FEMALE","55 Years",{"count":89,"type":90},684815,"ACTUAL","OBSERVATIONAL","This is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.",[94,95,96],"Esophageal Cancer","Squamous Cell Carcinoma","Adenocarcinoma","COMPLETED","2022-02-01",{"date":100,"type":90},"2022-02-03",{"date":102,"type":90},"2010-02-26",{"date":104,"type":90},"2012-02-16",{"name":5,"class":6}]